SERVIER

📅 Upcoming

🕒 Recent(90d)

News

• Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
  Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
  biopharma_dive · 5d ago
• Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
  Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.
  fiercebiotech · 5d ago
• Owkin, Servier ink oncology R&D deal to guide discovery and trial design
  AI drug discovery company Owkin has signed a pact with French drugmaker Servier to license Owkin’s AI scientist K Pro across Servier’s oncology discovery and trial operations.
  fiercebiotech · 8d ago
• Pfizer CFO to depart; GSK wins approval for UTI drug
  Plus news about Apellis Pharmaceuticals, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics. 👋 P…
  endpoints · 3mo ago
• Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation
  Shattuck Labs initiates $75M public offering: The US biotech {$STTK} is selling over 10.5 million shares for $4 apiece, and issuing pre-funded warrants for certain investors. The offering is set to…
  endpoints · 3mo ago
• STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
  Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
  stat · 3mo ago
• STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
  Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout
  stat · 3mo ago
• STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
  Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
  stat · 3mo ago
• STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
  Here is some of what you may have missed from the world's largest cancer research meeting.
  stat · 3mo ago
• Servier buys into muscular dystrophy with potentially $2.7B deal
  The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.
  biopharma_dive · 3mo ago